The role of E-cadherin/beta-catenin complex and cyclin D1 in head and neck squamous cell carcinoma.
OBJECTIVE
To determine the relationship between expression pattern of E-cadherin, beta-catenin and cyclin D1, and clinicopathologic parameters in patients with head and neck squamous cell carcinomas (HNSCC).


METHODS
The authors evaluated the immunohistochemical expression pattern of E-cadherin, beta-catenin in relationship with cyclin D1 overexpression, degree of histologic differentiation, clinical stage, and nodal status in 146 head and neck squamous cell carcinomas (HNSCC). The authors also evaluated the expression of E-cadherin/beta-catenin complex, E-cadherin/cyclin D1, and beta-catenin/cyclin D1 double staining with confocal laser scanning microscope.


RESULTS
Aberrant expressions in 78% of E-cadherin, 77% of beta-catenin, and 69% of cyclin D1 in the HNSCC were observed. There was correlation of aberrant expression of E-cadherin and nodal status. Cyclin D1 overexpression was also correlated to clinical stage and nodal status. Significant relation was observed between E-cadherin and beta-catenin expression patterns. Co-expression of E-cadherin and beta-catenin was significantly detected. However, there was no correlation of cyclin D1 overexpression with E-cadherin or beta-catenin expression patterns.


CONCLUSIONS
These results suggest that aberrant expression of E-cadherin, E-cadherin/beta-catenin complex, and cyclin D1 may be involved in clinical stage and/or nodal status, and analysis of the pattern of E-cadherin, cyclin D1, and E-cadherin/beta-catenin complex may be good prognostic marker of HNSCC.
Do
Nam Yong
NY
Department of Otorhinolaryngology, Chosun University College of Medicine, Gwangju, Korea.
Park
Sung Yong
SY
Lim
Sung Chul
SC
Cancer Res. 1993 Jul 15;53(14):3241-5
8324734
Int J Cancer. 2001 May 20;95(3):194-7
11307154
Cancer Res. 1994 Dec 1;54(23):6282-7
7954478
Nature. 1999 Apr 1;398(6726):422-6
10201372
Genes Dev. 1997 Dec 15;11(24):3286-305
9407023
J Clin Oncol. 2003 May 1;21(9):1708-14
12721245
Expert Rev Anticancer Ther. 2001 Jun;1(1):116-24
12113118
Cancer Res. 1961 Nov;21:1436-8
13880726
Cancer Res. 1996 Sep 15;56(18):4154-8
8797585
Biochem Biophys Res Commun. 1994 Nov 30;205(1):73-8
7999105
J Laryngol Otol. 2003 Apr;117(4):286-93
12816218
Trends Genet. 1993 Sep;9(9):317-21
8236461
Cancer. 1978 Mar;41(3):1170-8
638961
J Clin Pathol. 2001 Jan;54(1):42-7
11271788
Oral Oncol. 2003 Sep;39(6):610-8
12798405
Cell. 1991 May 31;65(5):849-57
1904011
Am J Pathol. 1995 Mar;146(3):605-12
7534041
Am J Pathol. 1997 Feb;150(2):705-11
9033283
Cell. 1993 May 7;73(3):499-511
8490963
Pathol Res Pract. 1993 Nov;189(9):975-8
8302730
Surg Clin North Am. 1996 Apr;76(2):327-41
8610267
Cancer Res Treat. 2003 Feb;35(1):16-24
26680910
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4262-6
10759547
J Cell Biol. 1992 Apr;117(2):415-25
1373144
Semin Cancer Biol. 1993 Aug;4(4):231-9
8400145